ZMB member Katharina Lückerath
ZMB Member
Katharina Lückerath
Next Member
Prof. Dr. Katharina Lückerath
Clinic for Nuclear Medicine
University Hospital Essen
Hufelandstr. 55
45122 Essen
- +49 201 723 86228
- Website
- Selected Publications
- Publication Metrics
-
- ZMB Research Program
Oncology
Research Overview
Our group focuses on theranostic approaches with the goal to deliver new insights into tumor biology, heterogeneity and metabolism and their relationship and relevance to functional imaging and biomarker-driven treatments in nuclear medicine.
Theranostics use radioligands that bind to cell surface receptors on target cells. Radioligands labeled with isotopes such as Gallium-68 or Fluor-18 enable imaging of target expression by positron emission tomography (PET). The same or a similar ligand labeled with alpha or beta radiation emitting isotopes delivers therapeutic radiation specifically to target expressing tissues (radionuclide therapy; RNT). In contrast to conventional radiotherapy, RNTs are systemically administered; as a consequence, metastases throughout the body can be targeted, and tumors are irradiated for hours to days.
Radionuclide therapy is a promising treatment option for various cancers. However, outcomes are rarely curative. We address this clinical need by investigating new RNT modalities and the mechanisms underlying the limited effectiveness of RNT. These mechanisms include, for example, tumor cell intrinsic resistance mechanisms, tumor protection by microenvironmental factors, and a suboptimal radiotherapeutic strategy. Poor understanding of these mechanisms represents a key barrier to the development of more effective RNT approaches. To improve radionuclide therapy outcomes and to establish rationally chosen, translatable RNT-based combination therapies, we characterize cancer mouse models and patient samples, and use diverse in vitro, ex vivo, and in vivo analyses to identify targetable RNT-induced alterations in tumor, stroma and immune cells that mitigate the effects of RNT and could be exploited therapeutically.
Read more
Selected Publications
-
18F-PSMA Cerenkov Luminescence and Flexible Autoradiography Imaging in a Prostate Cancer Mouse Model and First Results of a Radical Prostatectomy Feasibility Study in MenIn: Journal of Nuclear Medicine (JNM) Vol. 64 (2023) Nr. 4, pp. 598 - 604ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/
-
Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapyIn: Journal for ImmunoTherapy of Cancer Vol. 11 (2023) Nr. 10,ISSN: 2051-1426Online Full Text: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein Inhibitor Theranostics : Preclinical Combination TreatmentIn: PET Clinics Vol. 18 (2023) Nr. 3, pp. 409 - 418ISSN: 1879-9809; 1556-8598Online Full Text: dx.doi.org/
-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesIn: Journal of Nuclear Medicine (JNM) Vol. 64 (2023) Nr. 5, pp. 711 - 716ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/
-
Is There a Role of Artificial Intelligence in Preclinical Imaging?In: Seminars in Nuclear Medicine Vol. 53 (2023) Nr. 5, pp. 687 - 693ISSN: 1558-4623; 0001-2998Online Full Text: dx.doi.org/
-
Novel ⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine-Related PitfallsIn: Journal of Nuclear Medicine (JNM) Vol. 64 (2023) Nr. 3, pp. 368 - 371ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/ (Open Access)
-
PSMA-Directed Imaging and Therapy of Salivary Gland Tumors : A Single-Center Retrospective StudyIn: Journal of Nuclear Medicine (JNM) Vol. 64 (2023) Nr. 3, pp. 372 - 378ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/
-
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy ResponseIn: Molecular Cancer Research Vol. 21 (2023) Nr. 4, pp. 307 - 315ISSN: 1557-3125; 1541-7786Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Superior Tumor Detection for ⁶⁸Ga-FAPI-46 Versus ¹⁸F-FDG PET/CT and Conventional CT in Patients with CholangiocarcinomaIn: Journal of Nuclear Medicine (JNM) Vol. 64 (2023) Nr. 7, pp. 1049 - 1055ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/ (Open Access)
-
Tandem Isotope Therapy with ²²⁵Ac- and ¹⁷⁷Lu-PSMA-617 in a Murine Model of Prostate CancerIn: Journal of Nuclear Medicine (JNM) Vol. 64 (2023) Nr. 11, pp. 1772 - 1778ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/ (Open Access)
-
Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in MiceIn: Journal of Nuclear Medicine (JNM) Vol. 63 (2022) Nr. 9, pp. 1357 - 1363ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225In: EJNMMI Research Vol. 12 (2022) Nr. 1,ISSN: 2191-219XOnline Full Text: dx.doi.org/ (Open Access)
-
Pitfalls and Common Findings in ⁶⁸Ga-FAPI PET : A Pictorial AnalysisIn: Journal of Nuclear Medicine (JNM) Vol. 63 (2022) Nr. 6, pp. 890 - 896ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/ (Open Access)
-
Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell CarcinomaIn: Journal of Nuclear Medicine (JNM) Vol. 63 (2022) Nr. 3, pp. 396 - 398ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/ (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Vol. 28 (2022) Nr. 19, pp. 4346 - 4353ISSN: 1557-3265; 1078-0432Online Full Text: dx.doi.org/ (Open Access)
-
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancerIn: Nuclear Medicine and Biology Vol. 96-97 (2021) pp. 101 - 111ISSN: 1872-9614; 0969-8051Online Full Text: dx.doi.org/ (Open Access)
-
Enzalutamide enhances psma expression of psma-low prostate cancerIn: International Journal of Molecular Sciences (IJMS) Vol. 22 (2021) Nr. 14,ISSN: 1422-0067; 1661-6596Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Imaging Inflammation with Positron Emission TomographyIn: Biomedicines Vol. 9 (2021) Nr. 2, pp. 212ISSN: 2227-9059Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Immune-Checkpoint Blockade Enhances ²²⁵Ac-PSMA617 Efficacy in a Mouse Model of Prostate CancerIn: Journal of Nuclear Medicine (JNM) Vol. 62 (2021) Nr. 2, pp. 228 - 231ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/ (Open Access)
-
Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate CancerIn: Journal of Nuclear Medicine (JNM) Vol. 62 (2021) Nr. 7, pp. 989 - 995ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/ (Open Access)
-
PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman PrimatesIn: Clinical Cancer Research Vol. 27 (2021) Nr. 7, pp. 2050 - 2060ISSN: 1557-3265; 1078-0432Online Full Text: dx.doi.org/; Online Full Text: dx.doi.org/ (Open Access)
-
Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapyIn: Proceedings of the National Academy of Sciences of the United States of America (PNAS) Vol. 117 (2020) Nr. 26, pp. 15172 - 15181ISSN: 1091-6490; 0027-8424Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA HeterogeneityIn: Clinical Cancer Research Vol. 26 (2020) Nr. 12, pp. 2946 - 2955ISSN: 1557-3265; 1078-0432Online Full Text: dx.doi.org/ Online Full Text (Open Access)
-
Targeted alpha therapy in a systemic mouse model of prostate cancer : A feasibility studyIn: Theranostics Vol. 10 (2020) Nr. 6, pp. 2612 - 2620ISSN: 1838-7640Online Full Text: dx.doi.org/ (Open Access)
-
Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapyIn: British Journal of Haematology Vol. 184 (2019) Nr. 3, pp. 440 - 443ISSN: 1365-2141; 0007-1048Online Full Text: dx.doi.org/ (Open Access)
-
Detection Threshold and Reproducibility of ⁶⁸Ga-PSMA11 PET/CT in a Mouse Model of Prostate CancerIn: Journal of Nuclear Medicine (JNM) Vol. 59 (2018) Nr. 9, pp. 1392 - 1397ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/ (Open Access)
-
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancerIn: EJNMMI Research Vol. 8 (2018) Nr. 1,ISSN: 2191-219XOnline Full Text: dx.doi.org/ (Open Access)
-
CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple MyelomaIn: Theranostics Vol. 7 (2017) Nr. 6, pp. 1589 - 1597ISSN: 1838-7640Online Full Text: dx.doi.org/ (Open Access)
-
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate CancerIn: Journal of Nuclear Medicine (JNM) Vol. 58 (2017) Nr. 11, pp. 1786 - 1792ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/ (Open Access)
-
Targeting CXCR4 with [68Ga]Pentixafor : A suitable theranostic approach in pleural mesothelioma?In: OncoTarget Vol. 8 (2017) Nr. 57, pp. 96732 - 96737ISSN: 1949-2553Online Full Text: dx.doi.org/ (Open Access)
-
[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory valuesIn: Theranostics Vol. 7 (2017) Nr. 1, pp. 205 - 212ISSN: 1838-7640Online Full Text: dx.doi.org/ (Open Access)
-
¹¹C-Methionine-PET in Multiple Myeloma : A Combined Study from Two Different InstitutionsIn: Theranostics Vol. 7 (2017) Nr. 11, pp. 2956 - 2964ISSN: 1838-7640Online Full Text: dx.doi.org/ (Open Access)
-
First-in-human experience of CXCR4-directed endoradiotherapy with ¹⁷⁷Lu-and ⁹⁰Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra-and extramedullary diseaseIn: Journal of Nuclear Medicine (JNM) Vol. 57 (2016) Nr. 2, pp. 248 - 251ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Full Text: dx.doi.org/
-
¹¹C-methionine-PET in multiple myeloma : Correlation with clinical parameters and bone marrow involvementIn: Theranostics Vol. 6 (2016) Nr. 2, pp. 254 - 261ISSN: 1838-7640Online Full Text: dx.doi.org/ (Open Access)
-
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myelomaIn: EMBO Molecular Medicine Vol. 7 (2015) Nr. 4, pp. 477 - 487ISSN: 1757-4684; 1757-4676Online Full Text: dx.doi.org/ (Open Access)
-
¹¹C-Methionine-PET : A novel and sensitive tool for monitoring of early response to treatment in multiple myelomaIn: OncoTarget Vol. 6 (2015) Nr. 10, pp. 8418 - 8429ISSN: 1949-2553Online Full Text: dx.doi.org/ (Open Access)
-
¹⁸FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantationIn: OncoTarget Vol. 5 (2014) Nr. 17, pp. 7381 - 7391ISSN: 1949-2553Online Full Text: dx.doi.org/ (Open Access)
-
Targeting paraprotein biosynthesis for non-invasive characterization of myeloma biologyIn: PLoS ONE Vol. 8 (2013) Nr. 12, pp. e84840ISSN: 1932-6203Online Full Text: dx.doi.org/ (Open Access)
-
Immune modulation by Fas ligand reverse signaling : Lymphocyte proliferation is attenuated by the intracellular Fas ligand domainIn: Blood Vol. 117 (2011) Nr. 2, pp. 519 - 529ISSN: 1528-0020; 0006-4971Online Full Text: dx.doi.org/
-
The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cellsIn: Cell Death and Differentiation Vol. 14 (2007) Nr. 9, pp. 1678 - 1687ISSN: 1350-9047; 1476-5403Online Full Text: dx.doi.org/ (Open Access)